BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $68,000 | -36.4% | 6,421 | -2.5% | 0.00% | -100.0% |
| Q1 2022 | $107,000 | +23.0% | 6,587 | +5.5% | 0.00% | 0.0% |
| Q4 2021 | $87,000 | -22.3% | 6,246 | -20.1% | 0.00% | 0.0% |
| Q3 2021 | $112,000 | +36.6% | 7,817 | +50.5% | 0.00% | 0.0% |
| Q2 2021 | $82,000 | +54.7% | 5,193 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $53,000 | +20.5% | 5,193 | -11.2% | 0.00% | 0.0% |
| Q4 2020 | $44,000 | +76.0% | 5,850 | -17.6% | 0.00% | – |
| Q3 2020 | $25,000 | +47.1% | 7,100 | +104.5% | 0.00% | – |
| Q2 2020 | $17,000 | – | 3,472 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |